SMTL ID : 9bq6.1

Human Topoisomerase 2 Alpha ATPase domain bound to non-hydrolyzable ATP analog AMPPNP

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

homo-dimer

Ligands

2 x ANP: PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER(Non-covalent)

ANP.1: 27 residues within 4Å: Chain A: E.62, N.66, A.67, N.70, R.73, N.95, K.98, I.100, I.116, F.117, T.122, S.123, S.124, N.125, G.136, R.137, N.138, G.139, Y.140, G.141, A.142, K.143, T.190, Q.351, K.353 Chain B: Y.9 Ligands: MG.2 22 PLIP interactions: 21 interactions with chain A, 1 interactions with chain B Hydrogen bonds: A:N.66, A:N.66, A:S.123, A:S.124, A:S.124, A:S.124, A:N.125, A:R.137, A:N.138, A:N.138, A:G.139, A:Y.140, A:Y.140, A:G.141, A:A.142, A:K.143, A:Q.351, A:Q.351, A:K.353 Water bridges: A:N.95, B:Y.9 Salt bridges: A:K.143 ANP.3: 28 residues within 4Å: Chain A: Y.9 Chain B: E.62, N.66, A.67, N.70, R.73, N.95, K.98, I.100, I.116, F.117, T.122, S.123, S.124, N.125, G.136, R.137, N.138, G.139, Y.140, G.141, A.142, K.143, T.190, I.192, Q.351, K.353 Ligands: MG.4 21 PLIP interactions: 21 interactions with chain B Hydrogen bonds: B:N.66, B:N.95, B:S.123, B:S.124, B:S.124, B:S.124, B:N.125, B:R.137, B:N.138, B:N.138, B:G.139, B:Y.140, B:Y.140, B:G.141, B:A.142, B:T.190, B:Q.351, B:Q.351, B:K.353 Water bridges: B:N.66 Salt bridges: B:K.143

2 x MG: MAGNESIUM ION(Non-covalent)

MG.2: 4 residues within 4Å: Chain A: N.66, G.136, G.141 Ligands: ANP.1 No protein-ligand interaction detected (PLIP) MG.4: 4 residues within 4Å: Chain B: N.66, G.136, G.141 Ligands: ANP.3 No protein-ligand interaction detected (PLIP)

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Kubes, J. et al., Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. Nat Commun (2025)

Release Date

2025-06-25

Peptides

DNA topoisomerase 2-alpha: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

DNA topoisomerase 2-alpha

Related Entries With Identical Sequence